Press

Cannabis the wonder drug?

BMJ 2001; 323 doi: 10.1136/bmj.323.7321.1136 (Published 10 November 2001)
Cite this as: BMJ 2001;323:1136.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Trevor Jackson
  1. BMJ

    At a secret location in the home counties of England, 15 000 cannabis plants are being grown quite legally. They are being bred from strains whose names—Hindu Kush, Skunk, Northern Lights, Gloria—are redolent of the Amsterdam coffee house scene. Their psychoactive seed heads, which stand over two metres high, are carefully studied—but never smoked. For these plants are being cultivated as part of the world's first commercial trial of medicinal cannabis.

    The company behind the trial, GW Pharmaceuticals, based at Porton Down Science Park in Wiltshire, has had a rather good fortnight. Firstly, the home secretary, David Blunkett, announced on 23 October that the government would liberalise the law concerning possession and use of cannabis. He also indicated that he would be ready to license cannabis for medicinal use to treat multiple sclerosis and other conditions as soon as research trials were completed. Most commentators (including, albeit grudgingly, the Daily Mail leader writers) seemed to approve. On 24 October shares in GW Pharmaceuticals …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL